HS
APLS

HighVista Strategies’s Apellis Pharmaceuticals APLS Stock Holding History

HighVista Strategies’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-150,776
Closed -$3.79M – 163
2025
Q4 		$3.79M Buy
150,776
+5,047
+3% +$118K 0.98% 33
2025
Q3 		$3.3M Buy
145,729
+59,066
+68% +$1.38M 0.81% 37
2025
Q2 		$1.5M Sell
86,663
-22,051
-20% -$408K 0.55% 65
2025
Q1 		$2.38M Hold
108,714
– – 0.92% 22
2024
Q4 		$3.47M Buy
108,714
+72,739
+202% +$2.19M 1.29% 14
2024
Q3 		$1.04M Buy
35,975
+28,409
+375% +$1.05M 0.36% 101
2024
Q2 		$290K Buy
7,566
+300
+4% +$13.6K 0.11% 135
2024
Q1 		$427K Buy
+7,266
New +$463K 0.15% 124
2023
Q3 		– Sell
-30,242
Closed -$2.76M – 136
2023
Q2 		$2.76M Sell
30,242
-8,869
-23% -$765K 1.26% 21
2023
Q1 		$2.58M Hold
39,111
– – 2.1% 13
2022
Q4 		$2.02M Sell
39,111
-14,431
-27% -$765K 1.2% 28
2022
Q3 		$3.66M Buy
53,542
+7,401
+16% +$438K 2.09% 11
2022
Q2 		$2.09M Buy
46,141
+9,248
+25% +$422K 1.26% 25
2022
Q1 		$1.88M Buy
+36,893
New +$1.63M 1.19% 24
2021
Q4 		– Sell
-19,763
Closed -$651K – 72
2021
Q3 		$651K Buy
+19,763
New +$1.11M 0.43% 64

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

HighVista Strategies's APLS Position: Q1 2026 in Review

HighVista Strategies sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 150,776 shares — an estimated $3.79M sold.

HighVista Strategies first reported a position in APLS in Q3 2021 and held it in 15 quarters. The position peaked at $3.79M in Q4 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • HighVista Strategies reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HighVista Strategies sold 150,776 Apellis Pharmaceuticals shares in Q1 2026, an estimated $3.79M.
  • HighVista Strategies first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 15 quarters.
  • HighVista Strategies's Apellis Pharmaceuticals position peaked at $3.79M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.